Overview
- Regeneron became the 17th drugmaker to sign a most‑favored‑nation agreement Thursday, ending the administration’s yearlong effort to secure voluntary price cuts tied to the lowest levels in peer countries.
- Under the pact, Regeneron will extend lower prices to Medicaid and list its cholesterol drug Praluent at $225 on TrumpRx, a cash‑pay website that connects patients to direct manufacturer discounts.
- The FDA approved Regeneron’s gene therapy Otarmeni for a rare genetic form of deafness hours before the announcement, and the company will provide the treatment at no cost to eligible U.S. patients.
- The White House said participating companies receive three‑year relief from planned drug import tariffs, and it said Regeneron committed $27 billion to expand U.S. research and manufacturing capacity.
- HHS official Chris Klomp said the 17 deals touch about 86% of the branded market, while policy experts and Democrats questioned limited effects for people with private insurance or Medicare and pressed for disclosure of the confidential terms.